View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2022

Sesen Bio and Carisma enter deal to combine businesses

The Sesen Bio and Carisma boards of directors have granted unanimous approval for the deal.

Sesen Bio has signed a definitive merger agreement to combine its business with Carisma Therapeutics and create a clinical-stage biotechnology firm in an all-stock deal. 

Carisma develops chimeric antigen receptor macrophage (CAR-M) therapies and is said to be the only firm developing such therapies with proof of mechanism and safety findings shown in clinical trials. 

Its CAR-M platform offers the potential to modify the specific targets of immune cells, thereby facilitating several therapeutic applications in oncology and beyond. 

The first clinical use of the CAR-M cell therapy technology is CT-0508, which is currently being assessed by the company in a multicentre Phase I trial for advanced HER2+ solid tumours.

The merged business will focus on the advancement of Charisma’s cell therapy platform, which leverages engineered macrophages and monocytes to transform the way cancers and other serious ailments are treated. 

The combined business is anticipated to have nearly $180m in cash, cash equivalents and marketable securities at the transaction’s closing, including $30m from a concurrent financing by Carisma. 

The companies aim to use these cash proceeds to progress Carisma’s pipeline through several ongoing and anticipated key data readouts across various clinical trials. 

They will also be used for funding operating expenses and capital expenditure needs up to 2024. 

On closing of the deal, the merged company will be called Carisma Therapeutics, and its headquarters will be located in Philadelphia, Pennsylvania, US.

Carisma president and CEO Steven Kelly will lead the combined business.

The boards of directors of Sesen Bio and Carisma have granted unanimous approval for the deal.

Subject to the necessary approvals and closing conditions, the business combination is anticipated to conclude in the coming three to four months.

Kelly said: “This transaction will provide us with financial strength to not only continue to develop our lead candidate, CT-0508, but also allow us to accelerate the growth of our platform and pipeline within and outside of oncology and develop additional strong strategic partnerships beyond those we already have with Moderna and Novartis.”

Last August, the US Food and Drug Administration declined to grant approval for Sesen Bio’s biologics license application for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology